The Drug-Induced Respiratory Disease Website

Osimertinib

Rechallenge can lead to near-fatal or fatal relapse of AE/ILD

Publications

Li MSC, Lee KWC, Mok KKS, Loong HHF, Lam KC, Mok FST, Chan LL, Lau YM, Chan KP, Ng JTY, Wong WKY, Lam BHW, Chen ACC, Lee MMP, Chen OH, Mok TSK

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.

JTO clinical and research reports 2024 Apr;5;100648 — 2024 Apr — 100648

Diagnosing DIRD

Drug and radiation history

Drug singularity - Correct identification of the drug

Consistent timing of exposure v. onset of symptoms

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

Careful exlusion of another cause

Remission of symptoms with removal of drug

Recurrence with rechallenge (rarely advisable)

Causality assessment

Diagnosing DIRD

Identify causative drugs

LATEST CHANGELOG

No activity has been recorded yet.

View full changelog